.jpg)
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) today and set a price target of $40. The company’s shares opened today at $26.93, close to its 52-week high of $29.90.
Folkes noted:
“Collegium’s lead growth driver is Xtampza, which we believe could replace OxyContin as the largest branded oxycodone ER product. We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $40 price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $40 price target.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of 0.0% and a 52.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
Collegium Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.90 and a one-year low of $9.01. Currently, Collegium Pharmaceutical has an average volume of 426.9K.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.
